成田キャンパス
乳腺外科学教室

乳腺外科学教室

教室紹介

業績 2017年

英文論文

  1. Ishikawa T, Akazawa K, Hasegawa Y, Tanino H, Horiguchi J, Miura D, Hayashi M, Kohno N. Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer. J Surg Res 220:46-51, 2017
  2. Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, Kuwano H. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Med Mol Morphol 50(4):185-194, 2017
  3. Obayashi S, Horiguchi J, Higuchi T, Katayama A, Handa T, Altan B, Bai T, Bao P, Bao H, Yokobori T, Nishiyama M, Oyama T, Kuwano H. Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. Int J Oncol 51(3):781-790, 2017
  4. Katayama A, Handa T, Komatsu K, Togo M, Horiguchi J, Nishiyama M, Oyama T. Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome. Pathol Int 67(8):404-413, 2017
  5. Handa T, Katayama A, Yokobori T, Yamane A, Horiguchi J, Kawabata-Iwakawa R, Rokudai S, Bao P, Gombodorj N, Altan B, Kaira K, Asao T, Kuwano H, Nishiyama M, Oyama T. Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients. J Surg Oncol 116(6):706-715, 2017
  6. Kurozumi S, Matsumoto H, Hayashi Y, Tozuka K, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Kurosumi M. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer 17(1):354, 2017
  7. Arai H, Nobusawa S, Kawabata-Iwakawa R, Rokudai S, Higuchi T, Yamazaki T, Horiguchi J, Sano T, Kojima M, Nishiyama M, Yokoo H, Hirato J, Oyama T. Myeloid sarcoma arising in malignant phyllodes tumour: clonal relationships revealed by comparative genome-wide analyses. Br J Haematol 181(2):255-259, 2017
  8. Satoh T, Kaira K, Takahashi K, Takahashi N, Kanai Y, Asao T, Horiguchi J, Oyama T. Prognostic Significance of the Expression of CD98 (4F2hc) in Gastric Cancer. Anticancer Res 37(2):631-636, 2017
  9. Ogawa Y, Kunishima S, Yanagisawa K, Osaki Y, Uchiyama Y, Matsumoto N, Tokiniwa H, Horiguchi J, Nojima Y, Handa H. Successful management of perioperative hemostasis in a patient with Glanzmann thrombasthenia who underwent a right total mastectomy. Int J Hematol 105(2):221-225, 2017
  10. Okamura T, Nakajima Y, Katano-Toki A, Horiguchi K, Matsumoto S, Yoshino S, Yamada E, Tomaru T, Ishii S, Saito T, Ozawa A, Shibusawa N, Satoh T, Okada S, Nagaoka R, Takada D, Horiguchi J, Oyama T, Yamada M. Characteristics of Japanese aldosterone-producing adenomas with KCNJ5 mutations. Endocr J 64(1):39-47, 2017
  11. Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J. Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet 62(1):15-24, 2017

和文論文

  1. 堀口 淳:(乳癌の治療、乳癌の薬物療法と支持療法、内分泌療法.) 転移・再発乳癌の内分泌療法、日本臨床75巻 増刊号3、2017、pp321-325、日本臨床社
  2. 堀口 淳:閉経前術後内分泌療法の最新動向.医学のあゆみ265(5)2017、pp439-444,医歯薬出版株式会社